US Food and Drug Administration (FDA) has approved delandistrogene moxeparvovecrokl (also known as SRP 9001) for the treatment of ambulatory children (those who are able to walk unassisted) aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene (23 June 2023).
See more details in the document below.